Is LQDA or GHRS more profitable?

Liquidia has a net margin of 30.74% compared to GH Research's net margin of 0.00%. Liquidia's return on equity of 149.65% beat GH Research's return on equity. Company Net Margins Return on Equity Return on Assets Liquidia 30.74% 149.65% 36.30% GH Research N/A -20.07% -19.41%

Does the media favor LQDA or GHRS?

In the previous week, Liquidia had 15 more articles in the media than GH Research. MarketBeat recorded 16 mentions for Liquidia and 1 mentions for GH Research. Liquidia's average media sentiment score of 0.53 beat GH Research's score of 0.00 indicating that Liquidia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 10 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GH Research 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, GHRS or LNTH?

Lantheus has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GH Research N/A N/A -$48.26M -$1.00 N/A Lantheus $1.56B 4.19 $233.56M $4.14 24.15

Is GHRS or LNTH more profitable?

Lantheus has a net margin of 17.69% compared to GH Research's net margin of 0.00%. Lantheus' return on equity of 28.10% beat GH Research's return on equity. Company Net Margins Return on Equity Return on Assets GH Research N/A -20.07% -19.41% Lantheus 17.69% 28.10% 14.35%

Does the media prefer GHRS or LNTH?

In the previous week, Lantheus had 10 more articles in the media than GH Research. MarketBeat recorded 11 mentions for Lantheus and 1 mentions for GH Research. Lantheus' average media sentiment score of 1.26 beat GH Research's score of 0.00 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lantheus 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, GHRS or BLTE?

Belite Bio is trading at a lower price-to-earnings ratio than GH Research, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GH Research N/A N/A -$48.26M -$1.00 N/A Belite Bio N/A N/A -$77.61M -$2.73 N/A

Is GHRS or BLTE more profitable?

Belite Bio's return on equity of -11.84% beat GH Research's return on equity. Company Net Margins Return on Equity Return on Assets GH Research N/A -20.07% -19.41% Belite Bio N/A -11.84% -11.62%

Does the media prefer GHRS or BLTE?

In the previous week, Belite Bio had 2 more articles in the media than GH Research. MarketBeat recorded 3 mentions for Belite Bio and 1 mentions for GH Research. GH Research's average media sentiment score of 0.00 beat Belite Bio's score of -0.75 indicating that GH Research is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Belite Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Which has higher earnings and valuation, GHRS or DFTX?

GH Research is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GH Research N/A N/A -$48.26M -$1.00 N/A Definium Therapeutics N/A N/A -$183.79M -$3.43 N/A

Is GHRS or DFTX more profitable?

GH Research's return on equity of -20.07% beat Definium Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets GH Research N/A -20.07% -19.41% Definium Therapeutics N/A -84.01% -63.66%

Does the media refer more to GHRS or DFTX?

In the previous week, Definium Therapeutics had 8 more articles in the media than GH Research. MarketBeat recorded 9 mentions for Definium Therapeutics and 1 mentions for GH Research. Definium Therapeutics' average media sentiment score of 0.62 beat GH Research's score of 0.00 indicating that Definium Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Definium Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

GH Research (GHRS) Competitors

$28.33 -0.35 (-1.22%)

As of 08/21/2026 04:00 PM Eastern

Compare

GHRS vs. LQDA, LNTH, BLTE, DFTX, and AMRX

Should you buy GH Research stock or one of its competitors? GH Research's main competitors and comparable companies include Liquidia (LQDA), Lantheus (LNTH), Belite Bio (BLTE), Definium Therapeutics (DFTX), and Amneal Pharmaceuticals (AMRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does GH Research compare to Liquidia?

Liquidia (NASDAQ:LQDA) and GH Research (NASDAQ:GHRS) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

64.5% of Liquidia shares are owned by institutional investors. Comparatively, 56.9% of GH Research shares are owned by institutional investors. 25.6% of Liquidia shares are owned by insiders. Comparatively, 41.6% of GH Research shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Liquidia currently has a consensus price target of $98.08, suggesting a potential upside of 42.94%. GH Research has a consensus price target of $45.00, suggesting a potential upside of 58.84%. Given GH Research's stronger consensus rating and higher probable upside, analysts plainly believe GH Research is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45
GH Research	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Liquidia had 15 more articles in the media than GH Research. MarketBeat recorded 16 mentions for Liquidia and 1 mentions for GH Research. Liquidia's average media sentiment score of 0.53 beat GH Research's score of 0.00 indicating that Liquidia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	10 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GH Research	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GH Research has lower revenue, but higher earnings than Liquidia. GH Research is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	38.80	-$68.92M	$1.37	50.09
GH Research	N/A	N/A	-$48.26M	-$1.00	N/A

Liquidia has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market. Comparatively, GH Research has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market.

Liquidia has a net margin of 30.74% compared to GH Research's net margin of 0.00%. Liquidia's return on equity of 149.65% beat GH Research's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
GH Research	N/A	-20.07%	-19.41%

Summary

Liquidia beats GH Research on 10 of the 16 factors compared between the two stocks.

How does GH Research compare to Lantheus?

GH Research (NASDAQ:GHRS) and Lantheus (NASDAQ:LNTH) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

GH Research has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, meaning that its share price is 103% less volatile than the broader market.

Lantheus has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$1.00	N/A
Lantheus	$1.56B	4.19	$233.56M	$4.14	24.15

In the previous week, Lantheus had 10 more articles in the media than GH Research. MarketBeat recorded 11 mentions for Lantheus and 1 mentions for GH Research. Lantheus' average media sentiment score of 1.26 beat GH Research's score of 0.00 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lantheus	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

56.9% of GH Research shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 41.6% of GH Research shares are owned by company insiders. Comparatively, 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Lantheus has a net margin of 17.69% compared to GH Research's net margin of 0.00%. Lantheus' return on equity of 28.10% beat GH Research's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-20.07%	-19.41%
Lantheus	17.69%	28.10%	14.35%

GH Research presently has a consensus target price of $45.00, indicating a potential upside of 58.84%. Lantheus has a consensus target price of $108.11, indicating a potential upside of 8.14%. Given GH Research's stronger consensus rating and higher possible upside, equities research analysts clearly believe GH Research is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

Summary

Lantheus beats GH Research on 10 of the 15 factors compared between the two stocks.

How does GH Research compare to Belite Bio?

GH Research (NASDAQ:GHRS) and Belite Bio (NASDAQ:BLTE) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

56.9% of GH Research shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 41.6% of GH Research shares are owned by insiders. Comparatively, 13.3% of Belite Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Belite Bio's return on equity of -11.84% beat GH Research's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-20.07%	-19.41%
Belite Bio	N/A	-11.84%	-11.62%

Belite Bio is trading at a lower price-to-earnings ratio than GH Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$1.00	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

GH Research presently has a consensus target price of $45.00, suggesting a potential upside of 58.84%. Belite Bio has a consensus target price of $205.80, suggesting a potential upside of 27.78%. Given GH Research's stronger consensus rating and higher probable upside, research analysts clearly believe GH Research is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

GH Research has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market. Comparatively, Belite Bio has a beta of -1.22, suggesting that its stock price is 222% less volatile than the broader market.

In the previous week, Belite Bio had 2 more articles in the media than GH Research. MarketBeat recorded 3 mentions for Belite Bio and 1 mentions for GH Research. GH Research's average media sentiment score of 0.00 beat Belite Bio's score of -0.75 indicating that GH Research is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Belite Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

GH Research beats Belite Bio on 10 of the 13 factors compared between the two stocks.

How does GH Research compare to Definium Therapeutics?

GH Research (NASDAQ:GHRS) and Definium Therapeutics (NASDAQ:DFTX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

GH Research's return on equity of -20.07% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-20.07%	-19.41%
Definium Therapeutics	N/A	-84.01%	-63.66%

56.9% of GH Research shares are owned by institutional investors. Comparatively, 27.9% of Definium Therapeutics shares are owned by institutional investors. 41.6% of GH Research shares are owned by insiders. Comparatively, 2.4% of Definium Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

GH Research presently has a consensus target price of $45.00, indicating a potential upside of 58.84%. Definium Therapeutics has a consensus target price of $63.00, indicating a potential upside of 40.28%. Given GH Research's higher probable upside, analysts clearly believe GH Research is more favorable than Definium Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Definium Therapeutics had 8 more articles in the media than GH Research. MarketBeat recorded 9 mentions for Definium Therapeutics and 1 mentions for GH Research. Definium Therapeutics' average media sentiment score of 0.62 beat GH Research's score of 0.00 indicating that Definium Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Definium Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GH Research is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$1.00	N/A
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A

GH Research has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the broader market.

Summary

GH Research and Definium Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does GH Research compare to Amneal Pharmaceuticals?

GH Research (NASDAQ:GHRS) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

GH Research currently has a consensus price target of $45.00, indicating a potential upside of 58.84%. Amneal Pharmaceuticals has a consensus price target of $17.67, indicating a potential downside of 1.36%. Given GH Research's higher probable upside, equities analysts plainly believe GH Research is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00

GH Research has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market.

Amneal Pharmaceuticals has a net margin of 5.05% compared to GH Research's net margin of 0.00%. GH Research's return on equity of -20.07% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-20.07%	-19.41%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

Amneal Pharmaceuticals has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$1.00	N/A
Amneal Pharmaceuticals	$3.12B	1.83	$72.06M	$0.49	36.55

56.9% of GH Research shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 41.6% of GH Research shares are held by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, GH Research had 1 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 1 mentions for GH Research and 0 mentions for Amneal Pharmaceuticals. GH Research's average media sentiment score of 0.00 equaled Amneal Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
GH Research	Neutral
Amneal Pharmaceuticals	Neutral

Summary

Amneal Pharmaceuticals beats GH Research on 8 of the 15 factors compared between the two stocks.

Get GH Research News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GHRS vs. The Competition

Export

Metric	GH Research	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.94B	$12.54B	$7.37B	$12.85B
Dividend Yield	N/A	2.61%	2.53%	11.08%
P/E Ratio	-28.33	789.80	272.60	24.24
Price / Sales	N/A	764.50	618.96	99.81
Price / Cash	N/A	96.77	78.62	53.99
Price / Book	5.41	11.89	13.05	6.20
Net Income	-$48.26M	$2.81B	$3.47B	$348.59M
7 Day Performance	-3.93%	1.77%	2.09%	0.08%
1 Month Performance	2.53%	3.85%	6.64%	3.88%
1 Year Performance	116.59%	6.56%	25.02%	16.98%

GH Research Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GHRS GH Research	2.1345 of 5 stars	$28.33 -1.2%	$45.00 +58.8%	+116.6%	$1.94B	N/A	N/A	10	Positive News
LQDA Liquidia	4.2921 of 5 stars	$73.72 -5.1%	$98.08 +33.1%	+155.7%	$6.58B	$450.91M	53.68	50	Insider Trade
LNTH Lantheus	3.5626 of 5 stars	$100.54 -0.4%	$108.11 +7.5%	+71.7%	$6.56B	$1.54B	24.28	1,193	Positive News
BLTE Belite Bio	3.2347 of 5 stars	$163.56 +0.2%	$205.80 +25.8%	+150.1%	$6.56B	N/A	N/A	10	Analyst Downgrade
DFTX Definium Therapeutics	3.1165 of 5 stars	$45.49 +0.5%	$63.00 +38.5%	+340.7%	$6.11B	N/A	N/A	40	Analyst Forecast Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GHRS) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GH Research (GHRS) Competitors

GHRS vs. LQDA, LNTH, BLTE, DFTX, and AMRX

How does GH Research compare to Liquidia?

Summary

How does GH Research compare to Lantheus?

Summary

How does GH Research compare to Belite Bio?

Summary

How does GH Research compare to Definium Therapeutics?

Summary

How does GH Research compare to Amneal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHRS vs. The Competition

GH Research Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GH Research (GHRS) Competitors

GHRS vs. LQDA, LNTH, BLTE, DFTX, and AMRX

How does GH Research compare to Liquidia?

Do institutionals & insiders have more ownership in LQDA or GHRS?

Do analysts recommend LQDA or GHRS?

Does the media favor LQDA or GHRS?

Which has preferable valuation & earnings, LQDA or GHRS?

Which has more risk and volatility, LQDA or GHRS?

Is LQDA or GHRS more profitable?

Summary

How does GH Research compare to Lantheus?

Which has more risk and volatility, GHRS or LNTH?

Which has preferable earnings & valuation, GHRS or LNTH?

Does the media prefer GHRS or LNTH?

Do institutionals and insiders have more ownership in GHRS or LNTH?

Is GHRS or LNTH more profitable?

Do analysts rate GHRS or LNTH?

Summary

How does GH Research compare to Belite Bio?

Do institutionals & insiders hold more shares of GHRS or BLTE?

Is GHRS or BLTE more profitable?

Which has higher valuation & earnings, GHRS or BLTE?

Do analysts rate GHRS or BLTE?

Which has more volatility and risk, GHRS or BLTE?

Does the media prefer GHRS or BLTE?

Summary

How does GH Research compare to Definium Therapeutics?

Is GHRS or DFTX more profitable?

Do institutionals and insiders believe in GHRS or DFTX?

Do analysts prefer GHRS or DFTX?

Does the media refer more to GHRS or DFTX?

Which has higher earnings and valuation, GHRS or DFTX?

Which has more volatility and risk, GHRS or DFTX?

Summary

How does GH Research compare to Amneal Pharmaceuticals?

Do analysts recommend GHRS or AMRX?

Which has more risk and volatility, GHRS or AMRX?

Is GHRS or AMRX more profitable?

Which has stronger earnings and valuation, GHRS or AMRX?

Do institutionals & insiders believe in GHRS or AMRX?

Does the media prefer GHRS or AMRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHRS vs. The Competition

GH Research Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools